GoAI
Get started
NRx Pharmaceuticals, Inc. logo

NRx Pharmaceuticals, Inc.

NRXP

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$3.56

+$0.05 · +1.42%

Aug 21, 4:00 PM ET

Pre-market

$3.5207

−$0.0393 · -1.10%

Aug 24, 7:52 AM ET

NRXP company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

27

Expensive

Momentum

73

Gaining

Sentiment

43

Mixed

Risk resilience

37

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Jonathan C. Javitt
Listed since
Dec 4, 2017
Employees
29

Market position

Day range

Current $3.56

52-week range

Current $3.56

Open
$3.565
Previous close
$3.51
Volume
610.43K
0.49× average
Average volume
1.24M
Average daily volume
Market cap
61.54M USD
Beta
2.18
Market reference 1
50-day average
$3.7504
-5.08% below average
200-day average
$2.7993
+27.18% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
50.83M USD
EV / EBITDA
-1.83×
Earnings yield
-49.35%
Free cash flow yield
-24.33%

Profitability & efficiency

Return on equity
179.59%
Return on assets
-220.92%
Return on invested capital
106.00%

Financial health

Current ratio
0.31×

Financial statements

Income trends

Operating income

−16.22M USD+17.66%

Net income

−28.62M USD-13.91%
Income trends across reported periods−8.33M USD−39.92M USD−71.51M USD−103.1M USDOperating income, FY2021: −95.2M USDOperating income, FY2022: −44.34M USDOperating income, FY2023: −27.59M USDOperating income, FY2024: −19.7M USDOperating income, FY2025: −16.22M USDNet income, FY2021: −93.06M USDNet income, FY2022: −39.75M USDNet income, FY2023: −30.15M USDNet income, FY2024: −25.13M USDNet income, FY2025: −28.62M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −95.2M USD. Operating income FY2022 −44.34M USD. Operating income FY2023 −27.59M USD. Operating income FY2024 −19.7M USD. Operating income FY2025 −16.22M USD. Net income FY2021 −93.06M USD. Net income FY2022 −39.75M USD. Net income FY2023 −30.15M USD. Net income FY2024 −25.13M USD. Net income FY2025 −28.62M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue1.23M USD————
Cost of goods sold505K USD5K USD5K USD4K USD2K USD
Gross profit720K USD−5K USD−5K USD−4K USD−2K USD
Research and development3.78M USD6.2M USD13.37M USD17.03M USD20.26M USD
Selling, general, and administrative13.06M USD13.5M USD14.21M USD27.3M USD74.94M USD
Operating expenses16.94M USD19.7M USD27.58M USD44.33M USD95.2M USD
Interest income12K USD44K USD494K USD249K USD18 USD
Interest expense671K USD1.08M USD120K USD—18K USD
Depreciation and amortization143K USD5K USD5K USD4K USD2K USD
Operating income−16.22M USD−19.7M USD−27.59M USD−44.34M USD−95.2M USD
Net income−28.62M USD−25.13M USD−30.15M USD−39.75M USD−93.06M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-79.28%
11 comparable reports
Latest EPS result
-0.44
Estimate -0.11 · Miss by 312.49%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.28-0.17-0.62-1.07Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 17, 2025: actual -0.724, estimate -0.2, surprise -262.15%, Miss. Q2 2025, reported May 15, 2025: actual -0.34, estimate -0.3, surprise -13.33%, Miss. Q3 2025, reported Aug 18, 2025: actual -0.98, estimate -0.15, surprise -552.68%, Miss. Q4 2025, reported Nov 17, 2025: actual -0.27, estimate -0.11, surprise -145.45%, Miss. Q1 2026, reported Mar 23, 2026: actual 0.19, estimate -0.09, surprise +311.11%, Beat. Q2 2026, reported May 15, 2026: actual -0.04, estimate -0.05, surprise +20.00%, Beat. Q3 2026, reported Aug 17, 2026: actual -0.44, estimate -0.107, surprise -312.49%, Miss. Q4 2026, reported Nov 13, 2026: actual —, estimate -0.07, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates20.96M14.04M7.12M205.7KQ1 '25EstimateQ2 '25No estimateQ3 '25EstimateQ4 '25MissQ1 '26MissQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 17, 2025: actual —, estimate 5M USD, surprise —, Comparison unavailable. Q2 2025, reported May 15, 2025: actual 2.28M USD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 18, 2025: actual —, estimate 3.5M USD, surprise —, Comparison unavailable. Q4 2025, reported Nov 17, 2025: actual 242K USD, estimate 6.08M USD, surprise -96.02%, Miss. Q1 2026, reported Mar 23, 2026: actual 983K USD, estimate 7.53M USD, surprise -86.94%, Miss. Q2 2026, reported May 15, 2026: actual 1.07M USD, estimate 19.43M USD, surprise -94.50%, Miss. Q3 2026, reported Aug 17, 2026: actual 1.1M USD, estimate 1.33M USD, surprise -17.20%, Miss. Q4 2026, reported Nov 13, 2026: actual —, estimate 1.54M USD, surprise —, Comparison unavailable.

NRXP peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research NRXP

research.disclaimer